{"prompt": "Make reference to the context given to assess the scenario. If you do not know the answer. just say that \"I don't know\", don't try to make up an answer.\nYou are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC). Perform the following step\n\nANALYSE the given patient profile based on given query based on the following criteria:\n- Freshly treated patient or patient under maintenance\n- Prior response to Infliximab\n- Prior failure to Anti-TNF agents\n- Prior failure to Vedolizumab\n- Age\n- Pregnancy\n- Extraintestinale manifestations\n- Pouchitis\n\nFINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\n\nsummaries\n\nThe output should be formatted as a JSON instance that conforms to the JSON schema below.\n\nAs an example, for the schema {\"properties\": {\"foo\": {\"title\": \"Foo\", \"description\": \"a list of strings\", \"type\": \"array\", \"items\": {\"type\": \"string\"}}}, \"required\": [\"foo\"]}}\nthe object {\"foo\": [\"bar\", \"baz\"]} is a well-formatted instance of the schema. The object {\"properties\": {\"foo\": [\"bar\", \"baz\"]}} is not well-formatted.\n\nHere is the output schema:\n```\n{\"properties\": {\"drug_name\": {\"title\": \"Drug Name\", \"description\": \"Name of the drug\", \"type\": \"string\"}, \"advantages\": {\"title\": \"Advantages\", \"description\": \"Advantages of the drug \", \"type\": \"string\"}, \"disadvantages\": {\"title\": \"Disadvantages\", \"description\": \"Disadvantages of the drug\", \"type\": \"string\"}}, \"required\": [\"drug_name\", \"advantages\", \"disadvantages\"]}\n```\n\nQuestion: question\nAnswer:\n", "test_cases": [{"question": "40 year old male with newly diagnosed moderate UC and articular extraintestinal manifestations\n", "answer": "I don't know.", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "advanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 5, "text": "Trial and patient characteristics are summarized in\nTable 1. Overall, the median average age of patients was\n41 years (interquartile range, 40\u201342 y), and 60%\n(interquartile range, 56%\u201363%) were men. The median\ndisease duration was 6.7 years (interquartile range,\n6.0\u20137.8 y), and 49% (interquartile range, 46%\u201355%) of\npatients had extensive colitis. A median of 40% (inter-\nquartile range, 30%\u201350%) of patients were treated with\nconcomitant immunomodulators, and 51% (interquartile\nrange, 45%\u201357%) were on corticosteroids at baseline.\nPatients across all trials and treatment arms were com-\nparable in terms of baseline prognostic variables, inclu-\nsion/exclusion\ncriteria,\nand\nco-interventions.\nAll\noutcomes were assessed uniformly based on the stan-\ndard de\ufb01nition of the Mayo Clinic score, between weeks\n6 and 10 for induction therapy (in\ufb02iximab, adalimumab,\ntofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\nvedolizumab, 6 weeks, 10 weeks, and 14 weeks in"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 4, "text": "jIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%\u201318% had prior exposure to vedolizumab).\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2183"}, {"title": "", "filename": "otad009.pdf", "page": 1, "text": "2\nEfficacy and Safety of Advanced Therapies\nincidence ranges from 9 to 20 cases per 100 000 per year with \nhigher incidence in North America and Northern Europe.1\nThe advanced therapeutic armamentarium for adults \nwith moderately to severely active UC is rapidly evolving. \nFor over 20 years, biologics targeting specific inflamma-\ntory pathways have been the mainstay, beginning with those \ntargeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \nadalimumab [ADA], and golimumab [GOL]) followed by \nbiologics with other modes of action (eg, vedolizumab [VED] \nand ustekinumab [UST]). However, treatment limitations for \nmoderately to severely active UC remain, including primary \nnonresponse, secondary loss of response, immunogenicity, and \nparenteral administration.2 To overcome these limitations, \nthere has been increasing interest in small molecule drugs \n(SMDs), which can be orally administered and lack immu-\nnogenicity.3 Of particular interest are SMDs that inhibit the"}]}, {"question": "70 year old female with newly diagnosed severe UC\n", "answer": "I don't know.", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "advanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "actually have high severity (due to disease history or\nbehavior) increasing the risk for disease progression, and\nshould be managed more proactively and aggressively. We\nwill review predictors of IBD severity and activity.\nAge of In\ufb02ammatory Bowel Disease Diagnosis\nNumerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD"}, {"title": "", "filename": "otad009.pdf", "page": 1, "text": "2\nEfficacy and Safety of Advanced Therapies\nincidence ranges from 9 to 20 cases per 100 000 per year with \nhigher incidence in North America and Northern Europe.1\nThe advanced therapeutic armamentarium for adults \nwith moderately to severely active UC is rapidly evolving. \nFor over 20 years, biologics targeting specific inflamma-\ntory pathways have been the mainstay, beginning with those \ntargeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \nadalimumab [ADA], and golimumab [GOL]) followed by \nbiologics with other modes of action (eg, vedolizumab [VED] \nand ustekinumab [UST]). However, treatment limitations for \nmoderately to severely active UC remain, including primary \nnonresponse, secondary loss of response, immunogenicity, and \nparenteral administration.2 To overcome these limitations, \nthere has been increasing interest in small molecule drugs \n(SMDs), which can be orally administered and lack immu-\nnogenicity.3 Of particular interest are SMDs that inhibit the"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 4, "text": "jIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%\u201318% had prior exposure to vedolizumab).\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2183"}]}, {"question": "35 year old male with known moderate UC with prior exposure to infliximab but has worsening colitis on endoscopy despite compliance\n", "answer": "[\n{\n\"drug_name\": \"Vedolizumab\",\n\"advantages\": \"Vedolizumab is a good option for patients who have had prior exposure to TNF antagonists like infliximab. It is specifically designed to treat inflammation in the gut, which makes it a suitable choice for ulcerative colitis. It has been shown to be effective in inducing and maintaining remission in moderate to severe ulcerative colitis.\",\n\"disadvantages\": \"The main disadvantage of vedolizumab is that it may take longer to work compared to other biologics. It also requires intravenous administration, which can be inconvenient. Side effects can include headache, joint pain, nausea, and fever. There is also a risk of serious infections.\"\n},\n{\n\"drug_name\": \"Ustekinumab\",\n\"advantages\": \"Ustekinumab can be a good option for patients who have not responded to or cannot tolerate other biologics. It works by blocking a specific protein that causes inflammation, and can be used in patients with moderate to severe ulcerative colitis. It is administered via injection.\",\n\"disadvantages\": \"Potential side effects of ustekinumab include upper respiratory infections, headache, and fatigue. There is also a risk of serious infections, and it may not be as effective in patients who have previously failed other biologic therapies.\"\n}\n]", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1, "text": "ulcerative\ncolitis.\nStudies\nincluded\nin\nthese\nmeta-\nanalyses were phase II or III randomized controlled\ntrials (RCTs) that met the following inclusion criteria:\n(1) patients: adults (age, >18 y) with moderate to\nsevere ulcerative colitis (Mayo Clinic score of 6\u201312,\nwith an endoscopic subscore of 2 or 3) who were\neither\ntreatment-na\u00efve\n(\ufb01rst-line)\nor\npreviously\nexposed to TNFa antagonists (second-line); (2) inter-\nvention: biologic therapy with in\ufb02iximab, adalimumab,\ngolimumab, vedolizumab, tofacitinib, or ustekinumab,\nwith a minimum duration of therapy of 14 days; (3)\ncomparator: another active intervention or placebo;\nand (4) outcome: induction of clinical remission (Mayo\nClinic score of \ufffd2 with no individual subscore of >1)\nand endoscopic improvement (Mayo endoscopy sub-\nscore of 0 or 1).\nBecause trials of maintenance therapy of biologic\nagents had different designs (treat straight-through\ndesign vs rerandomizing responders to induction ther-"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 8, "text": "requiring hospitalization, IFX is the preferred biologic for\ninduction and maintenance of remission, with or without\nIMM. Combination therapy in the SUCCESS trial was asso-\nciated with improved clinical, but not endoscopic, outcomes\ncompared to IFX monotherapy.108 When using IFX as a\nmonotherapy in moderate to severe UC, given the potential\nfor the colon to act as a \u201csink\u201d for drugs, we advocate for\nchecking early drug concentrations to ensure proper dosing\nand detecting immunogenicity early along with other\npharmacokinetic and safety-related variables.109 There is no\nclear bene\ufb01t of concomitant mesalamine with biologic\ntherapy in UC and it can be stopped in patients escalating to\nbiologics.110 Some patients may present with acute severe\nUC\nwhere\nTNFi,\ncyclosporine,\nor\nsubtotal\ncolectomy\nfollowed by ileal pouch anal anastomosis can be a good\ninitial strategy; discussion of management of acute severe\nUC is beyond the scope of this article.\nTaking Extraintestinal Manifestation Into"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6, "text": "Figure 2. (A) Relative ef\ufb01-\ncacy\nof\ndifferent\nin-\nterventions for induction of\nclinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "METHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:\nIn biologic-na\u00efve patients, in\ufb02iximab was ranked highest for induction of clinical remission (OR\nvs placebo, 4.07; 95% CI, 2.67\u20136.21; SUCRA, 0.95) and endoscopic improvement (SUCRA, 0.95)"}]}, {"question": "60 year old female with newly diagnosed moderate UC with a background of congestive cardiac failure\n", "answer": "\"I don't know\"", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "advanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "actually have high severity (due to disease history or\nbehavior) increasing the risk for disease progression, and\nshould be managed more proactively and aggressively. We\nwill review predictors of IBD severity and activity.\nAge of In\ufb02ammatory Bowel Disease Diagnosis\nNumerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 4, "text": "jIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%\u201318% had prior exposure to vedolizumab).\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2183"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 6, "text": "Figure 2. (A) Relative ef\ufb01-\ncacy\nof\ndifferent\nin-\nterventions for induction of\nclinical\nremission\nand\nendoscopic\nimprovement\nin biologic-na\u00efve patients\nwith moderate to severely\nactive ulcerative colitis. (B)\nRelative\nef\ufb01cacy\nof\ndifferent interventions for\ninduction of clinical remis-\nsion\nand\nendoscopic\nimprovement\nin\npatients\nwith moderate to severely\nactive\nulcerative\ncolitis\nwith prior exposure to tu-\nmor necrosis factor (TNF)\u237a\nantagonists. SUCRA, sur-\nface under the cumulative\nranking.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2185"}]}, {"question": "38 year old female with newly diagnosed moderate UC and psoriasis\n", "answer": "[\n  {\n    \"drug_name\": \"Infliximab\",\n    \"advantages\": \"Infliximab is effective for induction therapy in moderate to severe UC. It is also beneficial in treating extraintestinal manifestations like psoriasis.\",\n    \"disadvantages\": \"Infliximab may not be effective in all patients and some may develop resistance or intolerance over time. Side effects can include infections, allergic reactions, and potential complications in pregnancy.\"\n  },\n  {\n    \"drug_name\": \"Ustekinumab\",\n    \"advantages\": \"Ustekinumab is effective in treating both UC and psoriasis. It is a newer drug and may be beneficial for patients who have not responded to or cannot tolerate other treatments.\",\n    \"disadvantages\": \"Ustekinumab may not be as effective as other drugs in severe cases of UC. Side effects can include infections, allergic reactions, and potential complications in pregnancy.\"\n  }\n]", "sources": [{"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 5, "text": "Trial and patient characteristics are summarized in\nTable 1. Overall, the median average age of patients was\n41 years (interquartile range, 40\u201342 y), and 60%\n(interquartile range, 56%\u201363%) were men. The median\ndisease duration was 6.7 years (interquartile range,\n6.0\u20137.8 y), and 49% (interquartile range, 46%\u201355%) of\npatients had extensive colitis. A median of 40% (inter-\nquartile range, 30%\u201350%) of patients were treated with\nconcomitant immunomodulators, and 51% (interquartile\nrange, 45%\u201357%) were on corticosteroids at baseline.\nPatients across all trials and treatment arms were com-\nparable in terms of baseline prognostic variables, inclu-\nsion/exclusion\ncriteria,\nand\nco-interventions.\nAll\noutcomes were assessed uniformly based on the stan-\ndard de\ufb01nition of the Mayo Clinic score, between weeks\n6 and 10 for induction therapy (in\ufb02iximab, adalimumab,\ntofacitinib, ustekinumab, 8 weeks; golimumab, 6 weeks;\nvedolizumab, 6 weeks, 10 weeks, and 14 weeks in"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 4, "text": "jIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%\u201318% had prior exposure to vedolizumab).\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2183"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 4, "text": "manifestations occur in up to 15% of IBD patients (Vavricka et al., 2011).\nThe most common, erythema nodosum, depends on the underlying dis-\nease activity, whereas pyoderma gangrenosum may be associated with\nactive or inactive intestinal disease and requires rapid management, most\ncommonly with systemic medication. Treatment includes oral cortico-\nsteroids, cyclosporine, tacrolimus and anti-TNF therapy (in\ufb02iximab or\nadalimumab), drugs that have good ef\ufb01cacy in several cases reports and\nsmall case series (Juillerat et al., 2007). Cases reports and a recent\nsemi-systematic review suggest that IBD cutaneous lesions may respond\nto the newer IBD drugs. This is the case for ustekinumab and less\nfrequently for vedolizumab (Phillips et al., 2020; Ben Abdallah et al.,\n2021). Uveitis also appears to respond to anti-TNF agents (Leal et al.,\n2019), whereas no biological agents, despite high expectations for\nvedolizumab, has shown ef\ufb01cacy in primary sclerosing cholangitis"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "severely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8 \nVermeire S, Danese S, Zhou W, et al. OP23 efficacy and safety of \nupadacitinib as induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from phase 3 \nU-ACCOMPLISH study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S021\u201322.\n9 \nThorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \nAdalimumab versus infliximab for the treatment of moderate to \nsevere ulcerative colitis in adult patients na\u00efve to anti-TNF therapy: \nan indirect treatment comparison meta-analysis. J Crohn\u2019s Colitis \n2014; 8: 571\u201381.\n10 \nDanese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \nmoderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review"}]}, {"question": "25 year old pregnant woman with severe distal ulcerative colitis\n", "answer": "\"I don't know\"", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "advanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "Downloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3, "text": "Disease Phenotype and Clinical Characteristics\nThe International Organization for the Study of In\ufb02am-\nmatory Bowel Disease and the American Gastroenterological\nAssociation (AGA) provide a framework for categorization of\nCD and UC severity into mild-, moderate-, and high-risk\ngroups based on phenotype and other characteristics.59,60\nIn CD, the presence of large or deep mucosal lesions on\nendoscopy or magnetic resonance imaging (MRI), history of\na \ufb01stula, abscess, or intestinal resection are predictors of\nworse outcomes.59,60 In a prospective population-based\ninception cohort of 213 patients with CD, penetrating\nbehavior was associated with a higher risk of progression to\nperianal disease (HR, 5.65; 95% CI, 2.65\u201312.03) and was a\nrisk factor for resection (HR, 3.92; 95% CI, 1.86\u20138.67) and\nhospitalization (HR, 1.01; 95% CI, 1.00\u20131.01).16 Ileal and\nupper gastrointestinal disease location and extensive dis-\nease are also markers of severe disease.61 Cigarette smoking"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "actually have high severity (due to disease history or\nbehavior) increasing the risk for disease progression, and\nshould be managed more proactively and aggressively. We\nwill review predictors of IBD severity and activity.\nAge of In\ufb02ammatory Bowel Disease Diagnosis\nNumerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD"}]}, {"question": "56 year old man with moderate to severe ulcerative colitis and ankylosing spondylitis\n", "answer": "I don't know.", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "advanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "severely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8 \nVermeire S, Danese S, Zhou W, et al. OP23 efficacy and safety of \nupadacitinib as induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from phase 3 \nU-ACCOMPLISH study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S021\u201322.\n9 \nThorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \nAdalimumab versus infliximab for the treatment of moderate to \nsevere ulcerative colitis in adult patients na\u00efve to anti-TNF therapy: \nan indirect treatment comparison meta-analysis. J Crohn\u2019s Colitis \n2014; 8: 571\u201381.\n10 \nDanese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \nmoderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "moderate-to-severe ulcerative colitis.\nMethods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \nCentral Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \nJuly 1, 2021. Major congresses\u2019 databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\ncontrolled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \nmolecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were \nincluded. Phase 2 RCTs were excluded because of their small sample sizes and inclusion of doses not further explored \nin phase 3 RCTs. Summary data from intention-to-treat analyses were extracted from included reports by JSL and PAO. \nThe primary outcome was the induction of clinical remission. A network meta-analysis was done under the frequentist"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "Aliment Pharmacol Ther 2010; 31: 693\u2013707.\n3 \nPaschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, \nTsapas A. Systematic review with network meta-analysis: the impact \nof medical interventions for moderate-to-severe ulcerative colitis on \nhealth-related quality of life. Aliment Pharmacol Ther 2018; \n48: 1174\u201385.\n4 \nOlivera P, Danese S, Peyrin-Biroulet L. Next generation of small \nmolecules in inflammatory bowel disease. Gut 2017; 66: 199\u2013209.\n5 \nOlivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in \ninflammatory bowel disease. Expert Rev Clin Immunol 2017; \n13: 693\u2013703.\n6 \nFeagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction \nand maintenance therapy for ulcerative colitis (SELECTION): \na phase 2b/3 double-blind, randomised, placebo-controlled trial. \nLancet 2021; 397: 2372\u201384. \n7 \nDanese S, Vermeire S, Zhou W, et al. OP24 efficacy and safety of \nupadacitinib induction therapy in patients with moderately to"}]}, {"question": "38 year old man with severe ulcerative colitis and has lost response to vedolizumab\n", "answer": "[\n{\n\"drug_name\": \"Infliximab\",\n\"advantages\": \"Infliximab is an anti-tumour necrosis factor biologic that has revolutionised therapeutics for ulcerative colitis, enabling better disease control in terms of increasing the rates of mucosal healing, deep remission, and corticosteroid-free remission, and improving quality of life.\",\n\"disadvantages\": \"Infliximab has several limitations, including limited efficacy, primary non-response, secondary loss of response, and immunogenicity.\"\n},\n{\n\"drug_name\": \"Ustekinumab\",\n\"advantages\": \"Ustekinumab has been shown to be superior to placebo for inducing clinical remission in patients with moderate to severe ulcerative colitis who have had prior exposure to both vedolizumab and TNFa antagonists.\",\n\"disadvantages\": \"The exact efficacy of Ustekinumab in patients who have lost response to vedolizumab is not clearly stated in the provided literature.\"\n}\n]", "sources": [{"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "colitis. Vedolizumab was the best performing agent for safety outcomes. With the paucity of direct comparisons in the \npublished literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "of life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7, "text": "Second-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-\nnumab, 13% to 18% patients had prior exposure to both\nvedolizumab and TNFa antagonists. These data were not\navailable for tofacitinib.\nInduction\nof\nclinical\nremission. On\ndirect\nmeta-\nanalysis, tofacitinib and ustekinumab, but not adalimu-\nmab or vedolizumab, were superior to placebo for induc-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 4, "text": "jIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%\u201318% had prior exposure to vedolizumab).\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2183"}]}, {"question": "28 year old woman who has severe extensive ulcerative colitis and has a history of lymphoma which was treated 4 years ago\n", "answer": "\"I don't know\"", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "advanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "moderate-to-severe ulcerative colitis.\nMethods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \nCentral Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \nJuly 1, 2021. Major congresses\u2019 databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\ncontrolled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \nmolecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were \nincluded. Phase 2 RCTs were excluded because of their small sample sizes and inclusion of doses not further explored \nin phase 3 RCTs. Summary data from intention-to-treat analyses were extracted from included reports by JSL and PAO. \nThe primary outcome was the induction of clinical remission. A network meta-analysis was done under the frequentist"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "severely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8 \nVermeire S, Danese S, Zhou W, et al. OP23 efficacy and safety of \nupadacitinib as induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from phase 3 \nU-ACCOMPLISH study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S021\u201322.\n9 \nThorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \nAdalimumab versus infliximab for the treatment of moderate to \nsevere ulcerative colitis in adult patients na\u00efve to anti-TNF therapy: \nan indirect treatment comparison meta-analysis. J Crohn\u2019s Colitis \n2014; 8: 571\u201381.\n10 \nDanese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \nmoderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "NGERE and Department of \nHepatogastroenterology, \nNancy University Hospital, \nLorraine University, \nVandoeuvre-l\u00e9s-Nancy, France \n(Prof L Peyrin-Biroulet MD) \nCorrespondence to: \nProf Laurent Peyrin-Biroulet, \nINSERM NGERE and Department \nof Hepatogastroenterology, \nNancy University Hospital, \nLorraine University, Vandoeuvre-\nl\u00e8s-Nancy F-54511, France \npeyrinbiroulet@gmail.com\nEfficacy and safety of biologics and small molecule drugs for \npatients with moderate-to-severe ulcerative colitis: \na systematic review and network meta-analysis \nJuan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\nSummary\nBackground There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \nto compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \nmoderate-to-severe ulcerative colitis."}]}, {"question": "36 year old woman with moderate ulcerative colitis and multiple sclerosis", "answer": "\"I don't know\"", "sources": [{"title": "", "filename": "otad009.pdf", "page": 0, "text": "advanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "moderate-to-severe ulcerative colitis.\nMethods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane \nCentral Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and \nJuly 1, 2021. Major congresses\u2019 databases from Jan 1, 2018, to July 3, 2021, were reviewed manually. Phase 3, placebo-\ncontrolled or head-to-head randomised controlled trials (RCTs) assessing the efficacy and safety of biologics or small \nmolecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were \nincluded. Phase 2 RCTs were excluded because of their small sample sizes and inclusion of doses not further explored \nin phase 3 RCTs. Summary data from intention-to-treat analyses were extracted from included reports by JSL and PAO. \nThe primary outcome was the induction of clinical remission. A network meta-analysis was done under the frequentist"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "NGERE and Department of \nHepatogastroenterology, \nNancy University Hospital, \nLorraine University, \nVandoeuvre-l\u00e9s-Nancy, France \n(Prof L Peyrin-Biroulet MD) \nCorrespondence to: \nProf Laurent Peyrin-Biroulet, \nINSERM NGERE and Department \nof Hepatogastroenterology, \nNancy University Hospital, \nLorraine University, Vandoeuvre-\nl\u00e8s-Nancy F-54511, France \npeyrinbiroulet@gmail.com\nEfficacy and safety of biologics and small molecule drugs for \npatients with moderate-to-severe ulcerative colitis: \na systematic review and network meta-analysis \nJuan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\nSummary\nBackground There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed \nto compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with \nmoderate-to-severe ulcerative colitis."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "patients with moderate to severe ulcerative colitis. More trials of direct comparisons are\nneeded to inform clinical decision making with greater con\ufb01dence.\nKeywords: GRADE; Pharmacotherapy; In\ufb02ammatory Bowel Disease; UC; Comparative Ef\ufb01cacy.\nU\nlcerative colitis affects 1 in 200 to 1 in 400 people\nin Western nations, and its global incidence and\nprevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and"}]}]}